Abstract 110P
Background
The human epidermal growth factor receptor 2 (HER2/neu), a member of epidermal growth factor receptor protein family, play a role as predictive and prognostic biomarkers in various tumor types, particularly biliary tract cancers (BTCs), a heterogeneous group of poor-prognosis solid tumors with limited treatment options. Accurate evaluating of HER2 overexpression is essential for selection and determination of eligible patients for HER2-directed therapy. Herein, we report the results of an immunohistochemistry (IHC) concordance study comparing the AmoyDx® HER-2(29D8) assay and the well-established Ventana PATHWAY anti-HER-2/neu (4B5) assay using a BTC cohort of 432 samples.
Methods
Performance of the AmoyDx® HER-2 (29D8) assay was compared against the Ventana PATHWAY anti-HER-2/neu (4B5) assay using 432 pre-selected BTC samples. Further ISH testing was successfully performed in 134 of the samples to identify HER2-positive and HER2-negative samples according to standard criteria.
Results
There was a high concordance between results from the AmoyDx 29D8 and PATHWAY 4B5 assays for HER2-negative (IHC 0, 1 +) and HER2-positive (IHC 2 + , 3 +) BTCs (98.38%, 425/432). When combined with the ISH results, the aggrement was even increased to 99.29% (422/425) (Table). In addition, the low concordance (34.63%, 9/26) between the two assays for IHC 1+ samples, indicating that the detecton criteria for HER2 IHC 0 and 1+ still need further clarification, which reminds researchers to carefully select appropriate assays if they focus on BTC with HER2-low expression types. Table: 110P
Comparison of HER2 scorings derived from the indicated assays
Ventana PATHWAY anti-HER-2/neu (4B5) | ||||
+ | - | Total | ||
AmoyDx® HER-2 (29D8) | + | 19 | 2 | 21 |
- | 1 | 403 | 404 | |
Total | 20 | 405 | 425 | |
Positive percent agreement | 95.00% (95%CI: 75.13%, 99.87%) | |||
Negative percent agreement | 99.51% (95%CI: 98.23%, 99.94%) | |||
Overall percent agreement | 99.29% (95%CI: 97.95%, 99.85%) |
Conclusions
Our data demonstrate that AmoyDx 29D8 exhibited high concordance with PATHWAY 4B5, and could provide critical information for the selection of HER2-targeted therapy for BTC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
W. Su, H. Lu, Z. Liu, Z. Tang, Z. Huang: Financial Interests, Personal, Full or part-time Employment: Amoy Diagnostics. L. Ruan, C. Zhu: Financial Interests, Personal, Advisory Board: Amoy Diagnostics. All other authors have declared no conflicts of interest.
Resources from the same session
669P - Patient-reported outcomes with selpercatinib in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial
Presenter: Hyunseok Kang
Session: Poster session 17
670P - Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study
Presenter: Panpan Zhang
Session: Poster session 17
671P - Safety and efficacy of PM060184 plus gemcitabine in advanced solid tumors
Presenter: Sanjay Goel
Session: Poster session 17
672P - Phase I/II trial of RVU120 (SEL120), CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
Presenter: Rafal Dziadziuszko
Session: Poster session 17
673P - A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
Presenter: Patrick Schoeffski
Session: Poster session 17
674P - Response of thrombopoietin receptor agonists in MDM2 inhibitor induced thrombocytopenia
Presenter: Raymond DeMatteo
Session: Poster session 17
675P - A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors
Presenter: Jinming Yu
Session: Poster session 17
676P - Preclinical characterization of novel peptide binders for EphA2-targeted radiopharmaceutical therapy
Presenter: Renee Clift
Session: Poster session 17
677P - Preliminary findings from a phase I, open-label, dose-finding study of SNB-101 in patients with advanced solid tumors
Presenter: Yun Beom Sang
Session: Poster session 17
678P - ExoDS: A bioengineered exosome-based capsule for targeted delivery of chemotherapy drugs to cancer cells and cancer stem cells
Presenter: Abhishek Dutta
Session: Poster session 17